ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,859Medicare Part D Prescriptions Filled, Including Refills

Rank: 46 out of 315

$593K Total Retail Price of All Prescriptions

Rank: 47 out of 315

475 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Hawaii
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 475 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

16% of this provider’s 475 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Risky Drugs to Seniors

2% of this provider’s 7,236 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

26% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$67 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 17.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Hawaii
SIMVASTATIN 589 534 1 1
LISINOPRIL 460 378 2 3
AMLODIPINE BESYLATE 261 228 3 2
ATORVASTATIN CALCIUM 248 219 4 5
FELODIPINE ER 241 241 5 23
METFORMIN HCL 231 198 6 7
HYDROCODONE-ACETAMINOPHEN 228 134 S3 7 19
LOSARTAN POTASSIUM 216 206 8 4
AMLODIPINE BESYLATE-BENAZEPRIL 202 185 9 26
WARFARIN SODIUM 185 153 10 20
FUROSEMIDE 161 143 11 15
OMEPRAZOLE 157 141 12 9
ZOLPIDEM TARTRATE 152 112 13 29
PREDNISONE 152 136 13 41
HYDROCHLOROTHIAZIDE 134 113 15 16
METOPROLOL TARTRATE 119 99 16 18
LEVOTHYROXINE SODIUM 118 114 17 6
OXYCODONE HCL 107 31 S2 18 57
CRESTOR 105 98 19 24
ATENOLOL 93 93 20 11
MORPHINE SULFATE ER 85 0 S2 21 128
ISOSORBIDE MONONITRATE ER 84 83 22 92
TAMSULOSIN HCL 82 81 23 21
ALLOPURINOL 81 77 24 14
CITALOPRAM HBR 79 75 25 72
PRAVASTATIN SODIUM 74 61 26 10
GLIPIZIDE 72 65 27 30
LOVASTATIN 71 71 28 8
OXYCONTIN 71 12 S2 28 192
ALENDRONATE SODIUM 70 70 30 12
FENOFIBRATE 70 66 30 43
DIGOXIN 68 55 32 45
PLAVIX 68 60 32 40
METOPROLOL SUCCINATE 66 66 34 13
DONEPEZIL HCL 66 66 34 28
GLYBURIDE-METFORMIN HCL 63 60 R 36 87
NAMENDA 62 62 37 38
CARVEDILOL 60 47 38 22
ADVAIR DISKUS 58 58 39 46
IBUPROFEN 56 39 40 89
FAMOTIDINE 54 43 41 75
CELEBREX 53 50 42 34
LOSARTAN-HYDROCHLOROTHIAZIDE 52 52 43 17
MORPHINE SULFATE 51 0 S2 44 235
BACLOFEN 51 29 44 184
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 7, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.